

# Conceptus Essure™ System

## Final Panel Package

### (PMA P020014)

## Table of Contents

### Volume 1

Cover Letter

Table of Contents – Panel Package

Summary of Safety and Effectiveness

Device Description/Mechanism of Action

Patient and Physician Labeling (Proposed)

**Exhibit 1** – Samples of Labeling Components

**Exhibit 2** – Instructions for Use

**Exhibit 3** – Patient Labeling

**Exhibit 4** – Rationale for Change in 3-Month Post-Procedure Follow Up

Professional Training Program

**Exhibit A** – Summary of Results To Date with Commercial Training Program

**Exhibit B** – Training Presentation and Video

**Exhibit C** – Training Handouts

### Volume 2

Pre-hysterectomy Study Report

**Exhibit A** – Summary of Results for Previous Designs

**Exhibit B** – Protocol

**Exhibit C** – Histology Photos (**Exhibit E** of Module III, Case Report Forms of **Exhibit E** not included)

Phase II Study Report

**Exhibit A** – Summary of Results with Beta Designs of the STOP Device

**Exhibit B** – Protocol Approved under the IDE

**Exhibit C** – Phase II Protocol Revision History

OUS Marketing/Clinical Trial Experience

**Volume 3**

Pivotal Trial Study Report

**Exhibit A** - FDA Correspondence

**Exhibit B** - Investigational Device Accountability

**Exhibit C** - Study Deviations

**Exhibit D** - Luteal Phase Pregnancies

**Exhibit E** - Predictors of Placement Failure

**Exhibit F** - Learning Curve Analysis

**Exhibit G** - Draft Manuscript

**Exhibit H** - Histology Picture from Perforated Micro-Inserts

**Exhibit I** - Censoring Analysis for Effectiveness Calculation

**Exhibit J** - Country-by-Country Analysis

**Exhibit K** - Adverse Events and Protocol Deviations listed by Investigational Site

**Volume 4**

Study Protocol

Informed Consent

Statistical Plan

**Volume 5**

References for Pivotal Trial Report

Table of Contents for PMA and Modules (previously submitted to FDA and included here for reference only).